What Akouos does

Akouos is a clinical-stage precision genetic medicine company developing adeno-associated virus (AAV) vector-based gene therapies targeting genetically driven forms of hearing loss and inner ear disorders. Founded in 2016 and headquartered in Boston, Massachusetts, the company builds on the Ancestral AAV (AAVAnc) Technology platform — exclusively licensed for inner ear applications from co-founder Dr. Luk H. Vandenberghe's laboratory at Massachusetts Eye and Ear — combined with a proprietary minimally invasive transcanal delivery approach designed to achieve consistent vector distribution along the cochlear sensory epithelium. Its portfolio includes lead candidate AK-OTOF (AAV gene therapy delivering a healthy otoferlin gene for OTOF-mediated hearing loss, currently in Phase 1/2), AK-antiVEGF (Phase 1/2 in vestibular schwannoma), and earlier-stage programs targeting CLRN1 (Usher Syndrome Type 3A), GJB2, autosomal dominant hearing loss, and hair cell regeneration.

The company's revenue model is presently that of a clinical-stage biotech with no commercial products: near-term value is realized through clinical advancement and eventual commercialization of gene therapy products, while the company also operates ancillary assets such as the Resonate no-charge genetic testing and counseling program (US, Brazil, Mexico) and The Sing Registry for genetic sensorineural hearing loss. Following Eli Lilly's October 2022 acquisition announcement (approximately $487 million upfront plus contingent milestone payments) and the November 2022 tender offer expiration, Akouos operates as a wholly owned subsidiary of Eli Lilly, with future commercial distribution expected to leverage Lilly's global pharmaceutical infrastructure.

Customer segmentation is structured around narrow genetic patient populations rather than enterprise accounts, with primary focus on OTOF-mediated hearing loss patients (severe-to-profound bilateral congenital hearing loss), followed by vestibular schwannoma, Usher Syndrome Type 3A, and GJB2-mediated hearing loss populations. Go-to-market centers on FDA regulatory pathways — AK-OTOF has received FDA Orphan Drug Designation, FDA Rare Pediatric Disease Designation, and European Commission Orphan Drug Designation — supplemented by patient advocacy partnerships (AG Bell, Hearing Loss Association of America, Global Genes, Usher Syndrome Society) and direct patient recruitment via dedicated clinical trial websites.

Name

Akouos

Legal name

Akouos, Inc.

Website

https://akouos.com

Company type

Private

Founded year

2016

Operating status

Acquired

Headcount range

101–250 employees

Short description

Akouos is a clinical-stage precision genetic medicine company developing AAV-based gene therapies for genetically driven hearing loss, with lead program AK-OTOF in Phase 1/2 trials. It operates as a wholly owned subsidiary of Eli Lilly following a 2022 acquisition.

Ownership category

akta.pro rank

Product category

Gene Therapy for Hearing Loss

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (54171), Scientific Research and Development Services (5417)

SIC

Surgical & Medical Instruments & Apparatus (3841), Services-Health Services (8000)

akta.pro primary industry

Otology & Neurotology (Ear/Hearing/Balance) (HLAKAMAC)

akta.pro secondary industries

Audiology & Hearing Services (ENT-Affiliated) (HLAKAMAI), Audiology & Hearing Diagnostic Centers (HLAFAKAH), Pediatric Otolaryngology (HLAKAMAB)

Keywords

• Gene therapy development
• Precision genetic medicine
• Inner ear therapeutics
• AAV gene therapies
• Hearing loss treatments

Headquarters

HQ city

Boston

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Gene Therapy Pipeline: Akouos is a clinical-stage precision genetic medicine company focused on developing AAV gene therapies for hearing loss. The company was acquired by Eli Lilly in October 2022 for approximately $487 million upfront with potential for additional milestone payments. As a wholly owned subsidiary, Akouos operates within Lilly's broader pharmaceutical portfolio. Revenue generation would come from FDA-approved gene therapy products following successful clinical development.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Core offering

Akouos is a clinical-stage precision genetic medicine company developing AAV vector-based gene therapies designed to restore, improve, and preserve hearing in patients with genetically defined inner ear disorders. Its lead programs are AK-OTOF, an intra-cochlear AAV gene therapy for OTOF-mediated hearing loss currently in Phase 1/2 clinical trials, and AK-antiVEGF for vestibular schwannoma also in Phase 1/2, with additional earlier-stage programs targeting CLRN1 (Usher Syndrome Type 3A), GJB2, autosomal dominant hearing loss, and hair cell regeneration.

Product overview

Akouos is a precision genetic medicine company developing a portfolio of AAV vector-based gene therapies targeting inner ear disorders. The company's core programs include AK-OTOF (lead program for OTOF-mediated hearing loss, in Phase 1/2), AK-antiVEGF (for vestibular schwannoma, in Phase 1/2), CLRN1 (for Usher Syndrome Type 3A), GJB2-mediated hearing loss, autosomal dominant hearing loss, and hair cell regeneration. The company also offers Resonate, a genetic testing and counseling program for sensorineural hearing loss, and maintains The Sing Registry for patient data. Akouos operates as a wholly owned subsidiary of Eli Lilly and Company following an October 2022 acquisition.

Differentiator

Problem solved

Functional benefit

Brands

• Resonate: A no-charge genetic testing and counseling program for sensorineural hearing loss using a comprehensive panel of nearly 300 genes.

Products and services

• AK-OTOF Adeno-associated virus (AAV) gene therapy for OTOF-mediated hearing loss, designed to deliver a healthy copy of the otoferlin gene to cochlear hair cells following a single inner ear administration to restore hearing. Currently in Phase 1/2 clinical trials in children with OTOF-mediated hearing loss and has received FDA Orphan Drug, FDA Rare Pediatric Disease, and European Commission Orphan Drug designations.
• AK-antiVEGF AAV gene therapy for vestibular schwannoma (acoustic neuroma) that delivers DNA sequences encoding anti-VEGF proteins to block tumor growth and preserve hearing. Currently in Phase 1/2 clinical trial.
• CLRN1 Program Gene therapy development program targeting Usher Syndrome Type 3A caused by CLRN1 gene mutations, designed to treat both hearing and vision components of the syndrome via hair cell targeting.
• GJB2 Program Gene therapy development program targeting GJB2-mediated hearing loss (connexin 26 mutations), addressing one of the most common genetic causes of congenital hearing loss by targeting supporting cells in the cochlea.
• Autosomal Dominant Hearing Loss Program Gene therapy development program for autosomal dominant hearing loss using AAV-enabled gene transfer combined with knockdown mechanisms to address dominant-negative mutations.
• Hair Cell Regeneration Program Research program targeting supporting cells in the cochlea with the goal of regenerating inner ear hair cells to address hearing loss beyond monogenic causes.
• Resonate by Akouos No-charge genetic testing and counseling program using a comprehensive panel of nearly 300 genes to identify genetic causes of sensorineural hearing loss; available to providers in the U.S., Brazil, and Mexico.

Quantifiable outcome

• 466 million people worldwide have disabling hearing loss with no FDA-approved pharmacologic therapies addressing underlying causes
• +1 more outcomes

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• Blueprint GeneticsminorStrategic or Co-development Partner · 11 January 2021Akouos and Blueprint Genetics announced the Resonate program to improve access to genetic testing for individuals with auditory neuropathy. Resonate is a no-charge genetic testing and counseling program sponsored by Akouos using a comprehensive panel of nearly 300 genes to potentially determine whether there is an underlying genetic cause of hearing loss. The program is available for providers in the U.S., Brazil, and Mexico.

Scale indicators7 records

Recent moves8 records

Expansion highlights6 records

Broad incumbents

• Eli Lilly and Company: Akouos's parent company since November 2022. Broad incumbent providing global pharma infrastructure and acting as ultimate decision-maker on Akouos's pipeline strategy and capital allocation.
• Regeneron Pharmaceuticals: Large biotech with a growing gene therapy franchise, including its 2023 acquisition of Decibel Therapeutics. Broad incumbent with overlapping capabilities in genetic medicine and direct hearing-loss ambitions.
• Voyager Therapeutics: Clinical-stage gene therapy company developing AAV-based therapies for CNS disorders. Comparable in AAV platform technology and gene therapy development expertise, though targeting different therapeutic areas.
• Astellas Pharma: Large Japanese pharma that acquired Audion Therapeutics to pursue inner-ear regenerative therapies for hearing loss. Broad incumbent with direct overlap in hearing-loss therapeutics ambitions.

Direct peers

• Decibel Therapeutics: Clinical-stage biotech developing AAV-based gene therapies for hearing and balance disorders, including OTOF programs. Acquired by Regeneron in 2023. Closest direct competitor in the inner-ear gene therapy category.
• Frequency Therapeutics: Clinical-stage biotech focused on hearing restoration through small-molecule activation of inner-ear progenitor cells. Direct peer in the broader hearing-loss therapeutics category, though using a different modality (small molecule vs. AAV).
• Sensorion: Clinical-stage European biotech developing therapies for hearing loss disorders, including genetic and vestibular indications. Comparable in therapeutic focus on inner-ear disorders and rare-disease strategy.
• Otonomy: Clinical-stage biotech developing sustained-exposure drug therapies for ear disorders including hearing loss and tinnitus. Direct peer in clinical-stage otology drug development with a similar focus on inner-ear delivery.

Emerging players

• Pipeline Therapeutics: Clinical-stage biotech developing regenerative therapies for hearing loss, including hair-cell regeneration approaches. Comparable in target indication (sensorineural hearing loss) and pipeline stage though with a non-AAV modality.

Others

• Cochlear Limited: Global leader in cochlear implant devices for severe-to-profound hearing loss. Not a gene-therapy competitor, but the dominant existing intervention for the same patient populations Akouos ultimately aims to address — and a key benchmark for treatment-center access.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/akouos
• Xx.com/akouosinc

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds3 records

Investors15 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Akouos